Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

N-cadherin stabilises neural identity by dampening anti-neural signals.

Punovuori K, Migueles RP, Malaguti M, Blin G, Macleod KG, Carragher NO, Pieters T, van Roy F, Stemmler MP, Lowell S.

Development. 2019 Oct 10. pii: dev.183269. doi: 10.1242/dev.183269. [Epub ahead of print]

2.

Resolving the fibrotic niche of human liver cirrhosis at single-cell level.

Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, Portman JR, Matchett KP, Brice M, Marwick JA, Taylor RS, Efremova M, Vento-Tormo R, Carragher NO, Kendall TJ, Fallowfield JA, Harrison EM, Mole DJ, Wigmore SJ, Newsome PN, Weston CJ, Iredale JP, Tacke F, Pollard JW, Ponting CP, Marioni JC, Teichmann SA, Henderson NC.

Nature. 2019 Oct 9. doi: 10.1038/s41586-019-1631-3. [Epub ahead of print]

PMID:
31597160
3.

An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.

Smith HW, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour CR, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack JP, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher NO, Unciti-Broceta A, Savage P, Basik M, van Hoef V, Larsson O, Cooper CL, Vargas Calderon AC, Beith J, Millar E, Selinger C, Giguère V, Park M, Harris LN, Varadan V, Andrechek ER, O'Toole SA, Topisirovic I, Muller WJ.

Nat Commun. 2019 Jul 1;10(1):2901. doi: 10.1038/s41467-019-10681-4.

4.

Mauritian Endemic Medicinal Plant Extracts Induce G2/M Phase Cell Cycle Arrest and Growth Inhibition of Oesophageal Squamous Cell Carcinoma in Vitro.

Rummun N, Hughes RE, Beesoo R, Li WW, Aldulaimi O, Macleod KG, Bahorun T, Carragher NO, Kagansky A, Neergheen-Bhujun VS.

Acta Naturae. 2019 Jan-Mar;11(1):81-90.

5.

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells.

Kitamura T, Doughty-Shenton D, Pollard JW, Carragher NO.

J Vis Exp. 2019 Jan 29;(143). doi: 10.3791/58841.

PMID:
30774138
6.

Evaluation of Machine Learning Classifiers to Predict Compound Mechanism of Action When Transferred across Distinct Cell Lines.

Warchal SJ, Dawson JC, Carragher NO.

SLAS Discov. 2019 Mar;24(3):224-233. doi: 10.1177/2472555218820805. Epub 2019 Jan 29.

7.

Reversal of proliferation deficits caused by chromosome 16p13.11 microduplication through targeting NFκB signaling: an integrated study of patient-derived neuronal precursor cells, cerebral organoids and in vivo brain imaging.

Johnstone M, Vasistha NA, Barbu MC, Dando O, Burr K, Christopher E, Glen S, Robert C, Fetit R, Macleod KG, Livesey MR, Clair DS, Blackwood DHR, Millar K, Carragher NO, Hardingham GE, Wyllie DJA, Johnstone EC, Whalley HC, McIntosh AM, Lawrie SM, Chandran S.

Mol Psychiatry. 2019 Feb;24(2):294-311. doi: 10.1038/s41380-018-0292-1. Epub 2018 Nov 6.

8.

ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells.

Sarvi S, Crispin R, Lu Y, Zeng L, Hurley TD, Houston DR, von Kriegsheim A, Chen CH, Mochly-Rosen D, Ranzani M, Mathers ME, Xu X, Xu W, Adams DJ, Carragher NO, Fujita M, Schuchter L, Unciti-Broceta A, Brunton VG, Patton EE.

Cell Chem Biol. 2018 Dec 20;25(12):1456-1469.e6. doi: 10.1016/j.chembiol.2018.09.005. Epub 2018 Oct 4.

9.

High-Dimensional Profiling: The Theta Comparative Cell Scoring Method.

Warchal SJ, Dawson JC, Carragher NO.

Methods Mol Biol. 2018;1787:171-181. doi: 10.1007/978-1-4939-7847-2_13.

PMID:
29736718
10.

Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach.

Mettang M, Meyer-Pannwitt V, Karpel-Massler G, Zhou S, Carragher NO, Föhr KJ, Baumann B, Nonnenmacher L, Enzenmüller S, Dahlhaus M, Siegelin MD, Stroh S, Mertens D, Fischer-Posovszky P, Schneider EM, Halatsch ME, Debatin KM, Westhoff MA.

Sci Rep. 2018 Apr 3;8(1):5527. doi: 10.1038/s41598-018-23592-z.

11.

Machine Learning Enables Live Label-Free Phenotypic Screening in Three Dimensions.

O'Duibhir E, Paris J, Lawson H, Sepulveda C, Shenton DD, Carragher NO, Kranc KR.

Assay Drug Dev Technol. 2018 Jan;16(1):51-63. doi: 10.1089/adt.2017.819.

PMID:
29345979
12.

High-Precision Photothermal Ablation Using Biocompatible Palladium Nanoparticles and Laser Scanning Microscopy.

Rubio-Ruiz B, Pérez-López AM, Bray TL, Lee M, Serrels A, Prieto M, Arruebo M, Carragher NO, Sebastián V, Unciti-Broceta A.

ACS Appl Mater Interfaces. 2018 Jan 31;10(4):3341-3348. doi: 10.1021/acsami.7b17282. Epub 2018 Jan 22.

13.

Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action.

Hearn JM, Hughes GM, Romero-Canelón I, Munro AF, Rubio-Ruiz B, Liu Z, Carragher NO, Sadler PJ.

Metallomics. 2018 Jan 24;10(1):93-107. doi: 10.1039/c7mt00242d.

PMID:
29131211
14.

Reverse Phase Protein Arrays and Drug Discovery.

Macleod KG, Serrels B, Carragher NO.

Methods Mol Biol. 2017;1647:153-169. doi: 10.1007/978-1-4939-7201-2_10.

PMID:
28809001
15.

Reverse Phase Protein Arrays elucidate mechanisms-of-action and phenotypic response in 2D and 3D models.

Pawlak M, Carragher NO.

Drug Discov Today Technol. 2017 Mar;23:7-16. doi: 10.1016/j.ddtec.2017.05.002. Epub 2017 May 30. Review.

PMID:
28647089
16.

Empirical drug discovery: a view from the proteome.

Lee JA, Carragher NO, Berg EL.

Drug Discov Today Technol. 2017 Mar;23:1-5. doi: 10.1016/j.ddtec.2017.05.003. No abstract available.

PMID:
28647081
17.

Global histone modification fingerprinting in human cells using epigenetic reverse phase protein array.

Partolina M, Thoms HC, MacLeod KG, Rodriguez-Blanco G, Clarke MN, Venkatasubramani AV, Beesoo R, Larionov V, Neergheen-Bhujun VS, Serrels B, Kimura H, Carragher NO, Kagansky A.

Cell Death Discov. 2017 Mar 6;3:16077. doi: 10.1038/cddiscovery.2016.77. eCollection 2017.

18.

Accelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screening.

O'Duibhir E, Carragher NO, Pollard SM.

Mol Cell Neurosci. 2017 Apr;80:198-207. doi: 10.1016/j.mcn.2016.11.001. Epub 2016 Nov 4. Review.

19.

Screening out irrelevant cell-based models of disease.

Horvath P, Aulner N, Bickle M, Davies AM, Nery ED, Ebner D, Montoya MC, Östling P, Pietiäinen V, Price LS, Shorte SL, Turcatti G, von Schantz C, Carragher NO.

Nat Rev Drug Discov. 2016 Nov;15(11):751-769. doi: 10.1038/nrd.2016.175. Epub 2016 Sep 12. Review.

PMID:
27616293
20.

Development of the Theta Comparative Cell Scoring Method to Quantify Diverse Phenotypic Responses Between Distinct Cell Types.

Warchal SJ, Dawson JC, Carragher NO.

Assay Drug Dev Technol. 2016 Sep;14(7):395-406. doi: 10.1089/adt.2016.730.

21.

Next-generation phenotypic screening.

Warchal SJ, Unciti-Broceta A, Carragher NO.

Future Med Chem. 2016 Jul;8(11):1331-47. doi: 10.4155/fmc-2016-0025. Epub 2016 Jun 30. Review.

PMID:
27357617
22.

Naturally Inspired Peptide Leads: Alanine Scanning Reveals an Actin-Targeting Thiazole Analogue of Bisebromoamide.

Johnston HJ, Boys SK, Makda A, Carragher NO, Hulme AN.

Chembiochem. 2016 Sep 2;17(17):1621-7. doi: 10.1002/cbic.201600257. Epub 2016 Aug 5.

23.

Bistability in the Rac1, PAK, and RhoA Signaling Network Drives Actin Cytoskeleton Dynamics and Cell Motility Switches.

Byrne KM, Monsefi N, Dawson JC, Degasperi A, Bukowski-Wills JC, Volinsky N, Dobrzyński M, Birtwistle MR, Tsyganov MA, Kiyatkin A, Kida K, Finch AJ, Carragher NO, Kolch W, Nguyen LK, von Kriegsheim A, Kholodenko BN.

Cell Syst. 2016 Jan 27;2(1):38-48. doi: 10.1016/j.cels.2016.01.003. Epub 2016 Jan 27.

24.

Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.

Fraser C, Dawson JC, Dowling R, Houston DR, Weiss JT, Munro AF, Muir M, Harrington L, Webster SP, Frame MC, Brunton VG, Patton EE, Carragher NO, Unciti-Broceta A.

J Med Chem. 2016 May 26;59(10):4697-710. doi: 10.1021/acs.jmedchem.6b00065. Epub 2016 May 4.

25.

ADF and Cofilin1 Control Actin Stress Fibers, Nuclear Integrity, and Cell Survival.

Kanellos G, Zhou J, Patel H, Ridgway RA, Huels D, Gurniak CB, Sandilands E, Carragher NO, Sansom OJ, Witke W, Brunton VG, Frame MC.

Cell Rep. 2015 Dec 1;13(9):1949-64. doi: 10.1016/j.celrep.2015.10.056. Epub 2015 Nov 19.

26.

FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis.

Qian BZ, Zhang H, Li J, He T, Yeo EJ, Soong DY, Carragher NO, Munro A, Chang A, Bresnick AR, Lang RA, Pollard JW.

J Exp Med. 2015 Aug 24;212(9):1433-48. doi: 10.1084/jem.20141555. Epub 2015 Aug 10.

27.

Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells.

Hearn JM, Romero-Canelón I, Munro AF, Fu Y, Pizarro AM, Garnett MJ, McDermott U, Carragher NO, Sadler PJ.

Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3800-5. doi: 10.1073/pnas.1500925112. Epub 2015 Jul 10.

28.

Palladium-mediated dealkylation of N-propargyl-floxuridine as a bioorthogonal oxygen-independent prodrug strategy.

Weiss JT, Carragher NO, Unciti-Broceta A.

Sci Rep. 2015 Mar 19;5:9329. doi: 10.1038/srep09329.

29.

The PI3K pathway balances self-renewal and differentiation of nephron progenitor cells through β-catenin signaling.

Lindström NO, Carragher NO, Hohenstein P.

Stem Cell Reports. 2015 Apr 14;4(4):551-60. doi: 10.1016/j.stemcr.2015.01.021. Epub 2015 Mar 5.

30.

N-alkynyl derivatives of 5-fluorouracil: susceptibility to palladium-mediated dealkylation and toxigenicity in cancer cell culture.

Weiss JT, Fraser C, Rubio-Ruiz B, Myers SH, Crispin R, Dawson JC, Brunton VG, Patton EE, Carragher NO, Unciti-Broceta A.

Front Chem. 2014 Jul 29;2:56. doi: 10.3389/fchem.2014.00056. eCollection 2014.

31.

Quantitative phenotypic and pathway profiling guides rational drug combination strategies.

Dawson JC, Carragher NO.

Front Pharmacol. 2014 May 28;5:118. doi: 10.3389/fphar.2014.00118. eCollection 2014. Review.

32.

Development and bioorthogonal activation of palladium-labile prodrugs of gemcitabine.

Weiss JT, Dawson JC, Fraser C, Rybski W, Torres-Sánchez C, Bradley M, Patton EE, Carragher NO, Unciti-Broceta A.

J Med Chem. 2014 Jun 26;57(12):5395-404. doi: 10.1021/jm500531z. Epub 2014 Jun 12.

33.

Developments in preclinical cancer imaging: innovating the discovery of therapeutics.

Conway JR, Carragher NO, Timpson P.

Nat Rev Cancer. 2014 May;14(5):314-28. doi: 10.1038/nrc3724. Epub 2014 Apr 17. Review.

PMID:
24739578
34.

Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach.

Weiss JT, Dawson JC, Macleod KG, Rybski W, Fraser C, Torres-Sánchez C, Patton EE, Bradley M, Carragher NO, Unciti-Broceta A.

Nat Commun. 2014;5:3277. doi: 10.1038/ncomms4277.

35.

Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma.

Westhoff MA, Zhou S, Nonnenmacher L, Karpel-Massler G, Jennewein C, Schneider M, Halatsch ME, Carragher NO, Baumann B, Krause A, Simmet T, Bachem MG, Wirtz CR, Debatin KM.

Mol Cancer Res. 2013 Dec;11(12):1611-23. doi: 10.1158/1541-7786.MCR-13-0435-T. Epub 2013 Oct 21.

36.

High-content analysis to leverage a robust phenotypic profiling approach to vascular modulation.

Isherwood BJ, Walls RE, Roberts ME, Houslay TM, Brave SR, Barry ST, Carragher NO.

J Biomol Screen. 2013 Dec;18(10):1246-59. doi: 10.1177/1087057113499775. Epub 2013 Oct 9.

PMID:
24108119
37.

Comparison of methods for image-based profiling of cellular morphological responses to small-molecule treatment.

Ljosa V, Caie PD, Ter Horst R, Sokolnicki KL, Jenkins EL, Daya S, Roberts ME, Jones TR, Singh S, Genovesio A, Clemons PA, Carragher NO, Carpenter AE.

J Biomol Screen. 2013 Dec;18(10):1321-9. doi: 10.1177/1087057113503553. Epub 2013 Sep 17.

38.

Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer.

Nobis M, McGhee EJ, Morton JP, Schwarz JP, Karim SA, Quinn J, Edward M, Campbell AD, McGarry LC, Evans TR, Brunton VG, Frame MC, Carragher NO, Wang Y, Sansom OJ, Timpson P, Anderson KI.

Cancer Res. 2013 Aug 1;73(15):4674-86. doi: 10.1158/0008-5472.CAN-12-4545. Epub 2013 Jun 7.

39.

Advanced intravital subcellular imaging reveals vital three-dimensional signalling events driving cancer cell behaviour and drug responses in live tissue.

Nobis M, Carragher NO, McGhee EJ, Morton JP, Sansom OJ, Anderson KI, Timpson P.

FEBS J. 2013 Nov;280(21):5177-97. doi: 10.1111/febs.12348. Epub 2013 Jun 28. Review.

40.

Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.

Karim SA, Creedon H, Patel H, Carragher NO, Morton JP, Muller WJ, Evans TR, Gusterson B, Sansom OJ, Brunton VG.

J Pathol. 2013 Aug;230(4):430-40. doi: 10.1002/path.4202.

PMID:
23616343
41.

Combining imaging and pathway profiling: an alternative approach to cancer drug discovery.

Carragher NO, Brunton VG, Frame MC.

Drug Discov Today. 2012 Mar;17(5-6):203-14. Review.

PMID:
22493783
42.

Advancing cancer drug discovery towards more agile development of targeted combination therapies.

Carragher NO, Unciti-Broceta A, Cameron DA.

Future Med Chem. 2012 Jan;4(1):87-105. doi: 10.4155/fmc.11.169. Review.

PMID:
22168166
43.

FLIM-FRET imaging in vivo reveals 3D-environment spatially regulates RhoGTPase activity during cancer cell invasion.

McGhee EJ, Morton JP, Von Kriegsheim A, Schwarz JP, Karim SA, Carragher NO, Sansom OJ, Anderson KI, Timpson P.

Small GTPases. 2011 Jul;2(4):239-244. Epub 2011 Jul 1.

44.

The calpain system and cancer.

Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG.

Nat Rev Cancer. 2011 May;11(5):364-74. doi: 10.1038/nrc3050. Review.

PMID:
21508973
45.

Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53.

Timpson P, McGhee EJ, Morton JP, von Kriegsheim A, Schwarz JP, Karim SA, Doyle B, Quinn JA, Carragher NO, Edward M, Olson MF, Frame MC, Brunton VG, Sansom OJ, Anderson KI.

Cancer Res. 2011 Feb 1;71(3):747-57. doi: 10.1158/0008-5472.CAN-10-2267. Epub 2011 Jan 25.

46.

Live cell in vitro and in vivo imaging applications: accelerating drug discovery.

Isherwood B, Timpson P, McGhee EJ, Anderson KI, Canel M, Serrels A, Brunton VG, Carragher NO.

Pharmaceutics. 2011 Apr 4;3(2):141-70. doi: 10.3390/pharmaceutics3020141.

47.

High-content phenotypic profiling of drug response signatures across distinct cancer cells.

Caie PD, Walls RE, Ingleston-Orme A, Daya S, Houslay T, Eagle R, Roberts ME, Carragher NO.

Mol Cancer Ther. 2010 Jun;9(6):1913-26. doi: 10.1158/1535-7163.MCT-09-1148. Epub 2010 Jun 8.

48.

Real-time study of E-cadherin and membrane dynamics in living animals: implications for disease modeling and drug development.

Serrels A, Timpson P, Canel M, Schwarz JP, Carragher NO, Frame MC, Brunton VG, Anderson KI.

Cancer Res. 2009 Apr 1;69(7):2714-9. doi: 10.1158/0008-5472.CAN-08-4308. Epub 2009 Mar 24.

49.

Profiling distinct mechanisms of tumour invasion for drug discovery: imaging adhesion, signalling and matrix turnover.

Carragher NO.

Clin Exp Metastasis. 2009;26(4):381-97. doi: 10.1007/s10585-008-9222-y. Epub 2008 Oct 29. Review.

PMID:
18958576
50.

Assaying calpain activity.

Carragher NO.

Methods Mol Biol. 2007;370:109-20.

PMID:
17416991

Supplemental Content

Loading ...
Support Center